Kenya reports 2nd Ebola death as Nigeria races to understand transmission of index patient - CIDRAP

Kenya has reported a second death from Bundibugyo Ebola, a 65-year-old woman related to the index patient. Seven positive patients remain in isolation, and officials report no new cases. Nigeria’s only known patient, a 42-year-old Ugandan woman, was transferred to Switzerland in stable condition but may still be infectious.

The Uganda link comes from travel histories. The Kenyan index patient arrived through Uganda from the Democratic Republic of the Congo on October 3. The Nigerian patient and her husband had also recently traveled to Uganda. Africa CDC said both index patients passed through Entebbe International Airport that day, making it a possible shared exposure point.

Investigators are sending scientists to Nigeria and continuing contact monitoring. Kenya has identified 135 contacts of its first patient, while Nigeria is monitoring 52. The airport connection could clarify whether transmission occurred there or elsewhere during travel.

Bundibugyo Ebola is illness caused by Bundibugyo ebolavirus, a distinct Ebola virus species. The article reports this virus in Kenya. The difference matters because “Ebola” describes a group of related viruses, not one identical virus. Their biology and response to medical countermeasures can differ.

The DRC outbreak described in the article involves Ebola Zaire. The article identifies Ervebo as a vaccine targeting the Ebola Zaire strain. It also says Inmazeb reduced mortality by about 55% in trials conducted on Ebola Zaire. Those products therefore cannot automatically be assumed to work equally well against Bundibugyo virus.

Kenya’s cases are being treated with supportive hospital care, while the article does not name a Bundibugyo-specific vaccine or antibody treatment. The three-way vaccine trial in the DRC is aimed at Zaire Ebola. Matching countermeasures to the virus species remains important for outbreak control.

Kenya has seven positive patients still receiving treatment in isolation units. The country has also reported two deaths: its index patient died on October 5, and a 65-year-old close relative later died while quarantined. Officials identified 135 contacts of the first patient and placed 118 in quarantine; some completed the 21-day period and were released.

Nigeria has one reported Ebola patient, its index case, who was clinically improved and transferred to Switzerland. Her spouse traveled with her and remained asymptomatic. Nigeria is monitoring 52 case contacts. The article does not report additional Nigerian infections.

These figures describe known cases and tracked contacts, not necessarily every person exposed. Kenya’s seven patients remain in care, while Nigeria’s patient continues to be monitored abroad. Both countries are using isolation, quarantine, and contact follow-up to detect further illness quickly.

Clinical improvement means symptoms and test results are getting better, but it does not automatically prove that infectious virus has disappeared. Nigeria’s health minister said the patient was stable, conscious, communicating, and nearing baseline laboratory results, yet still potentially infectious. That is why strict protocols remained in place during her transfer.

Close contacts need monitoring because Ebola symptoms may appear after an exposure rather than immediately. Health teams watch contacts for fever or other symptoms, check their health status, and separate anyone who becomes ill. The article reports that Kenya quarantined contacts and released the first group only after completing 21 days.

This approach protects families, healthcare workers, and communities. It also helps investigators identify transmission chains before they expand. A patient’s recovery and a contact’s lack of symptoms are reassuring, but neither alone ends the need for precautions.

Investigators would first build detailed timelines for the Kenyan and Nigerian index patients. They could review travel records, interview the patients and companions, identify people encountered at Entebbe, and compare the timing of symptoms. A shared airport visit on October 3 would be important, but it would not by itself prove transmission.

Contact tracing could reveal whether either patient met someone infectious at the airport or elsewhere in Uganda. Investigators could also compare virus samples from patients and other detected cases. Genetic similarities might support a shared transmission chain, while different sequences could point toward separate exposures.

The article says Africa CDC is sending scientists to Nigeria after finding no travel to the DRC in the patient’s itinerary. Nigeria is monitoring 52 contacts, and Kenya has identified 135 contacts. Those investigations may show whether Entebbe was the common source or only part of the travel route.

Ebola control depends on safe clinics and protected health workers. When a nurse is killed or a health worker is attacked, staff may fear entering affected areas. Patients and families may also avoid treatment sites. Delayed care makes it harder to isolate sick people and provide supportive treatment.

The article reports that a nurse was killed and a health worker attacked outside an Ebola clinic in Tshopo province, DRC. This occurred at a facility treating Ebola patients. The World Health Organization director-general said everyone protecting communities must work in dignity and safety, and that healthcare must be protected.

If access breaks down, contact tracing and other outbreak measures also become harder. Missed contacts can continue normal activities without monitoring. The DRC outbreak is already far from controlled, so attacks threaten both immediate patient care and broader response efforts. Safety is therefore a public-health requirement, not just a workplace concern.

Vaccines prepare the immune system to recognize a virus before infection. Antibody treatments provide laboratory-made antibodies after exposure or illness; these antibodies bind virus particles and help the body control them. Their usefulness depends on whether they recognize the virus causing the outbreak.

The article describes Ervebo as a vaccine targeting Ebola Zaire. It also reports a three-way trial comparing Ervebo with experimental vaccines from Moderna, Oxford, and the Serum Institute of India. Inmazeb is a three-antibody cocktail that reduced mortality by about 55% in trials involving Ebola Zaire.

Kenya’s outbreak involves Bundibugyo Ebola, while the DRC outbreak involves Ebola Zaire. Therefore, success against Zaire cannot simply be assumed for Bundibugyo. Researchers must test vaccines and treatments against the relevant virus. Matching products correctly helps guide protection, trials, and emergency stockpiling.